Thursday, February 7, 2013

Clinipace named to FORBES "Most Promising Companies" list

CED Member Clinipace Worldwide, a global digital contract research organization (dCRO), today announced that the company has been listed at No. 36 on FORBES annual ranking of America’s Most Promising Companies -- a list of 100 privately held, high-growth companies with bright futures.
Clinipace has closed four global acquisitions over the past three years. Most recently, Clinipace acquired Paragon Biomedical, expanding its therapeutic expertise, site management capabilities, and clinical operations. In addition, the company extended its global footprint with the addition of offices in Irvine, California, High Wycombe, United Kingdom, and Trivandrum, India. Clinipace now employs over 450 individuals globally.This prestigious list is based on growth (both in sales and hiring), quality of management team and investors, margins, market size and key partnerships.
“It is an honor to be named to FORBES’ ranking of America’s Most Promising Companies,” said Jeff Williams, CEO, Clinipace Worldwide. “We owe this achievement to the dedication and expertise of our employees who work tirelessly to deliver a new service delivery model with which we are changing and improving the way clinical trials are run through a technology-enabled platform.”
Clinipace raised $13.2 million from six investors in just two weeks in September 2012, and an additional $9 million Series C-2 round led by Harbert Venture Partners and acquired Paragon Biomedical in October 2012. 

No comments:

Post a Comment